ClinicalTrials.gg
RecruitingNCT07311200Updated Apr 24, 2026

A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)

A Phase 2 interventional study of D-2570 and D-2570 Placebo in Active Systemic Lupus Erythematosus, sponsored by InventisBio Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by InventisBio Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
62nd of 245
120 · median 36
Started
2026
with 55 others
Phase 2
33 of 266
14 open now
Primary completion
2028-08
later than 158 of 190 live
Registered
216th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 62nd largest by planned enrollment of the 245 interventional ones that give a count, is one of 56 that started in 2026, is one of 33 in phase 2, reaches primary completion later than 158 of the 190 other live ones, and was the 216th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.

Read the detailed description

Subjects who sign the informed consent form will enter the screening period, during which their eligibility will be assessed according to the inclusion and exclusion criteria. Eligible participants who meet the inclusion criteria and do not meet any exclusion criteria will be randomized. Participants will then be assigned to one of the following groups: Group A, Group B, Group C, or the placebo group. They will proceed to the treatment period, during which they will take the corresponding investigational product once daily for 48 consecutive weeks. After completing the treatment, subjects will undergo safety follow-up. Throughout the treatment period, both investigators and subjects will remain blinded. During the study, participants will be required to provide pharmacokinetic and pharmacodynamic blood samples at the time points specified in the trial protocol.

03

Conditions studied

  • Active Systemic Lupus Erythematosus

Keywords

  • Active Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient voluntarily participates in this study after full .
  • The age is 18 years ≤ age ≤ 70 years, regardless of gender.
  • Diagnosed with Systemic Lupus Erythematosus (SLE) at least ≥ 24 weeks prior to screening.
  • SLEDAI-2K total score ≥ 8.
  • On stable treatment for systemic lupus erythematosus at least 4 weeks prior to randomization, and should remain at a stable dose throughout the trial period.

Exclusion criteria

Exclusion Criteria:

  • History of infection as defined in the protocol.
  • Any of the medical diseases or disorders listed in the protocol.
  • Significant, uncontrolled or unstable disease in any organ.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Group A: D-2570 and placebo

    Drug: D-2570 · Drug: D-2570 Placebo

  • Experimental
    Group B: D-2570 and placebo

    Drug: D-2570 · Drug: D-2570 Placebo

  • Experimental
    Group C: D-2570

    Drug: D-2570

  • Placebo comparator
    Placebo Control Group

    Drug: D-2570 Placebo

Interventions

  • DrugD-2570

    Participants will be assigned to one of the following groups: Group A, Group B, Group C, or the placebo control group.

  • DrugD-2570 Placebo

    D-2570 Placebo

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving the Systemic Lupus Erythematosus Responder Index-4 (SRI-4) at Week 32

    Time frame: Week 32

Secondary outcomes

  1. Proportion of subjects achieving SRI-4 at Weeks 4, 12, 24, and 48

    Time frame: Weeks 4, 12, 24, and 48

  2. Proportion of subjects achieving Systemic Lupus Erythematosus Responder Index-6 (SRI-6) at Weeks 4, 12, 24, 32, and 48

    Time frame: Weeks 4, 12, 24, 32, and 48

  3. Improvement rate in the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score from baseline at Weeks 4, 12, 24, 32, and 48

    Time frame: Weeks 4, 12, 24, 32, and 48

  4. Proportion of subjects with a Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score improvement of ≥50% from baseline at Weeks 4, 12, 24, 32, and 48, among those with a baseline CLASI activity score of ≥10

    Time frame: Weeks 4, 12, 24, 32, and 48

  5. Proportion of subjects with ≥6 active (tender or swollen) joints at baseline who achieve a reduction of ≥50% in active (tender or swollen) joint count from baseline at Weeks 4, 12, 24, 32, and 48

    Time frame: Weeks 4, 12, 24, 32, and 48

  6. Proportion of subjects achieving the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at Weeks 4, 12, 24, 32, and 48

    Time frame: Weeks 4, 12, 24, 32, and 48

  7. Proportion of subjects achieving Lupus Low Disease Activity State (LLDAS) at Weeks 4, 12, 24, 32, and 48

    Time frame: Weeks 4, 12, 24, 32, and 48

  8. Proportion of subjects with a prednisone dose of ≤5.0 mg/day or a reduction of ≥25% from baseline dose during Weeks 44-48

    Time frame: Weeks 44-48

  9. Changes from baseline of anti-double-stranded DNA (dsDNA) antibody

    Time frame: From enrollment to the end of treatment at 48 weeks

  10. blood drug concentration of D-2570

    Time frame: From enrollment to the end of treatment at 48 weeks

  11. Incidence of adverse events rate based on NCI CTCAE V5.0

    Time frame: From enrollment to 52 weeks

  12. Changes from baseline of complement (C3) levels

    Time frame: From enrollment to the end of treatment at 48 weeks

  13. Changes from baseline of complement C4 levels

    Time frame: From enrollment to the end of treatment at 48 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Aug 2028, 30 months after the start.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's planned 30 months is close to that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartActual
Feb 12, 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07311200
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Feb 12, 2026
Primary completion
Aug 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 24, 2026

Study contacts

Hang Ren, Master
Contact
hang.ren@inventisbio.com
86+15900699091
Xiaofeng
principal investigator · Zeng

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: D-2570

Start the discussion